The concept is currently mainly based on pre-clinical observations, highlighting the potential of combined targeting of VEGFR2, PDL1 and LTβ in enhancing HEV and TLS formation and, consequently, in tumor destruction (Allen et al., 2017; Colbeck et al., 2017b). The gene discussed is CD274; the disease is neoplasm.